Symbols / SGMO $0.30 -0.43% Sangamo Therapeutics, Inc.

Healthcare • Biotechnology • United States • NCM
SGMO Chart
About

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A. Its preclinical development products focus on tauopathies, ALS/FTD, and huntington's diseases Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 123.79M
Enterprise Value 130.17M Income -122.93M Sales 39.55M
Book/sh -0.04 Cash/sh 0.05 Dividend Yield —
Payout 0.00% Employees — IPO —
P/E — Forward P/E 11.20 PEG —
P/S 3.13 P/B -7.29 P/C —
EV/EBITDA -1.25 EV/Sales 3.29 Quick Ratio 0.74
Current Ratio 0.84 Debt/Eq — LT Debt/Eq —
EPS (ttm) -0.44 EPS next Y 0.03 EPS Growth —
Revenue Growth 88.40% Earnings 2026-05-11 ROA -83.66%
ROE -28.92% ROIC — Gross Margin -184.87%
Oper. Margin -175.49% Profit Margin 0.00% Shs Outstand 414.27M
Shs Float 405.91M Short Float 9.07% Short Ratio 8.03
Short Interest — 52W High 0.84 52W Low 0.21
Beta 1.50 Avg Volume 6.73M Volume 855.81K
Target Price $3.75 Recom Buy Prev Close $0.30
Price $0.30 Change -0.43%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$3.75
Mean price target
2. Current target
$0.29
Latest analyst target
3. DCF / Fair value
$-2.47
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.29
Low
$1.00
High
$10.00
Mean
$3.75

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-02-10 reit HC Wainwright & Co. Buy → Buy $10
2025-11-07 down Barclays Overweight → Equal-Weight $1
2025-09-04 reit HC Wainwright & Co. Buy → Buy $10
2025-06-24 reit HC Wainwright & Co. Buy → Buy $10
2025-05-14 main Barclays Overweight → Overweight $5
2025-04-07 reit HC Wainwright & Co. Buy → Buy $10
2025-03-18 reit RBC Capital Sector Perform → Sector Perform $2
2025-01-27 reit HC Wainwright & Co. Buy → Buy $10
2025-01-23 main Truist Securities Buy → Buy $5
2025-01-02 reit HC Wainwright & Co. Buy → Buy $10
2024-12-31 main Jefferies Buy → Buy $3
2024-12-31 main Wells Fargo Equal-Weight → Equal-Weight $2
2024-12-20 reit HC Wainwright & Co. Buy → Buy $10
2024-12-19 reit HC Wainwright & Co. Buy → Buy $10
2024-12-10 reit HC Wainwright & Co. Buy → Buy $10
2024-11-14 reit HC Wainwright & Co. Buy → Buy $10
2024-11-14 main Barclays Overweight → Overweight $9
2024-11-05 main HC Wainwright & Co. Buy → Buy $10
2024-10-23 reit HC Wainwright & Co. Buy → Buy $5
2024-10-22 reit HC Wainwright & Co. Buy → Buy $5
News
RSS: Latest SGMO news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-06-12 MARKELS JOHN Director — 25,000 $0.00 $0
2025-06-12 HORN MARGARET A Director — 25,000 $0.00 $0
2025-06-12 MEYERS JAMES ROBERT Director — 25,000 $0.00 $0
2025-06-12 CAREY ROBERT F. Director — 25,000 $0.00 $0
2025-06-12 PARKER H STEWART Director — 25,000 $0.00 $0
2025-06-12 HILLAN KENNETH J. Director — 25,000 $0.00 $0
2025-06-12 SMITH KAREN LESLEY M.D. PH.D. Director — 25,000 $0.00 $0
2025-06-12 BEERS COURTNEY Director — 25,000 $0.00 $0
2025-02-25 MACRAE SANDY Chief Executive Officer — 375,000 $0.00 $0
2025-02-25 DURAIBABU PRATHYUSHA Chief Financial Officer — 120,000 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
39.55
-31.57%
57.80
-67.20%
176.23
+58.34%
111.30
Operating Revenue
39.55
-31.57%
57.80
-67.20%
176.23
+58.34%
111.30
Operating Expense
147.56
-5.56%
156.25
-47.07%
295.22
-5.55%
312.58
Research And Development
112.67
+1.03%
111.52
-52.35%
234.06
-6.34%
249.90
Selling General And Administration
34.89
-22.00%
44.73
-26.88%
61.17
-2.42%
62.68
General And Administrative Expense
34.89
-22.00%
44.73
-26.88%
61.17
-2.42%
62.68
Other Gand A
34.89
-22.00%
44.73
-26.88%
61.17
-2.42%
62.68
Total Expenses
147.56
-5.56%
156.25
-47.07%
295.22
-5.55%
312.58
Operating Income
-108.00
-9.71%
-98.45
+17.27%
-118.99
+40.88%
-201.28
Total Operating Income As Reported
-121.24
-16.61%
-103.97
+62.06%
-274.00
-36.13%
-201.28
EBITDA
-100.40
-12.70%
-89.09
+7.97%
-96.80
+46.44%
-180.72
Normalized EBITDA
-87.17
-4.31%
-83.57
-243.55%
58.21
+132.21%
-180.72
Reconciled Depreciation
7.60
-18.79%
9.36
-57.82%
22.19
+7.93%
20.56
EBIT
-108.00
-9.71%
-98.45
+17.27%
-118.99
+40.88%
-201.28
Total Unusual Items
-13.23
-139.72%
-5.52
+96.44%
-155.01
0.00
Total Unusual Items Excluding Goodwill
-13.23
-139.72%
-5.52
+96.44%
-155.01
0.00
Special Income Charges
-13.23
-139.72%
-5.52
+96.44%
-155.01
0.00
Impairment Of Capital Assets
13.23
+139.72%
5.52
-96.44%
155.01
0.00
Net Income
-122.93
-25.52%
-97.94
+62.01%
-257.83
-34.09%
-192.28
Pretax Income
-123.50
-25.88%
-98.11
+62.68%
-262.90
-37.04%
-191.85
Net Non Operating Interest Income Expense
1.30
-13.95%
1.51
-86.37%
11.10
+17.71%
9.43
Net Interest Income
1.30
-13.95%
1.51
-86.37%
11.10
+17.71%
9.43
Interest Income Non Operating
1.30
-13.95%
1.51
-86.37%
11.10
+17.71%
9.43
Interest Income
1.30
-13.95%
1.51
-86.37%
11.10
+17.71%
9.43
Other Income Expense
-16.80
-1332.05%
-1.17
+99.24%
-155.01
—
Other Non Operating Income Expenses
-3.56
-181.95%
4.35
—
—
Tax Provision
-0.57
-240.12%
-0.17
+96.71%
-5.07
-1282.28%
0.43
Tax Rate For Calcs
0.00
+170.21%
0.00
-91.18%
0.00
-90.81%
0.00
Tax Effect Of Unusual Items
-0.06
-547.70%
-0.01
+99.69%
-2.99
0.00
Net Income Including Noncontrolling Interests
-122.93
-25.52%
-97.94
+62.01%
-257.83
-34.09%
-192.28
Net Income From Continuing Operation Net Minority Interest
-122.93
-25.52%
-97.94
+62.01%
-257.83
-34.09%
-192.28
Net Income From Continuing And Discontinued Operation
-122.93
-25.52%
-97.94
+62.01%
-257.83
-34.09%
-192.28
Net Income Continuous Operations
-122.93
-25.52%
-97.94
+62.01%
-257.83
-34.09%
-192.28
Minority Interests
—
—
0.00
0.00
Normalized Income
-109.76
-18.75%
-92.43
+12.64%
-105.81
+44.97%
-192.28
Net Income Common Stockholders
-122.93
-25.52%
-97.94
+62.01%
-257.83
-34.09%
-192.28
Diluted EPS
-0.44
+10.20%
-0.49
+66.89%
-1.48
-18.40%
-1.25
Basic EPS
-0.44
+10.20%
-0.49
+66.89%
-1.48
-18.40%
-1.25
Basic Average Shares
280.19
+38.92%
201.70
+15.62%
174.44
+13.02%
154.34
Diluted Average Shares
280.19
+38.92%
201.70
+15.62%
174.44
+13.02%
154.34
Diluted NI Availto Com Stockholders
-122.93
-25.52%
-97.94
+62.01%
-257.83
-34.09%
-192.28
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
59.74
-41.22%
101.64
-38.52%
165.32
-70.61%
562.51
Current Assets
35.83
-30.68%
51.69
-45.20%
94.33
-68.59%
300.33
Cash Cash Equivalents And Short Term Investments
20.95
-50.03%
41.92
-48.25%
81.00
-70.82%
277.63
Cash And Cash Equivalents
20.95
-50.03%
41.92
-7.27%
45.20
-55.00%
100.44
Other Short Term Investments
—
0.00
-100.00%
35.80
-79.80%
177.19
Receivables
10.51
+128.64%
4.60
+13.06%
4.07
-9.06%
4.47
Accounts Receivable
0.37
-29.47%
0.53
-43.01%
0.92
-74.90%
3.68
Taxes Receivable
10.14
+149.07%
4.07
+29.52%
3.14
—
Accrued Interest Receivable
—
—
0.40
-49.24%
0.79
Prepaid Assets
—
—
—
18.22
Other Current Assets
4.37
-15.57%
5.17
-44.11%
9.26
-49.19%
18.22
Total Non Current Assets
23.91
-52.12%
49.94
-29.65%
70.99
-72.92%
262.18
Net PPE
14.11
-59.41%
34.76
-34.26%
52.87
-57.89%
125.53
Gross PPE
56.32
-24.48%
74.57
-28.23%
103.91
-35.88%
162.06
Accumulated Depreciation
-42.21
-6.01%
-39.82
+22.00%
-51.05
-39.74%
-36.53
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
3.55
+0.00%
3.55
-23.08%
4.61
-19.56%
5.73
Construction In Progress
—
0.00
-100.00%
1.09
-92.64%
14.77
Other Properties
30.94
-32.89%
46.10
-32.60%
68.41
-38.37%
110.99
Leases
21.83
-12.40%
24.92
-16.39%
29.81
-2.50%
30.57
Goodwill And Other Intangible Assets
—
—
0.00
-100.00%
88.28
Goodwill
—
—
0.00
-100.00%
37.55
Other Intangible Assets
—
—
—
50.73
Investments And Advances
—
—
0.00
-100.00%
29.84
Non Current Accounts Receivable
8.94
-30.22%
12.81
-16.62%
15.36
—
Other Non Current Assets
0.87
-63.39%
2.38
-13.96%
2.77
-85.07%
18.52
Total Liabilities Net Minority Interest
74.01
-6.15%
78.86
-4.33%
82.43
-69.19%
267.55
Current Liabilities
42.47
-7.29%
45.80
-4.04%
47.73
-57.27%
111.71
Payables And Accrued Expenses
22.14
+14.34%
19.37
-43.41%
34.22
-0.23%
34.30
Payables
14.44
-6.77%
15.48
+1.48%
15.26
-31.93%
22.42
Accounts Payable
14.44
-6.77%
15.48
+1.48%
15.26
-31.93%
22.42
Current Accrued Expenses
7.71
+98.53%
3.88
-79.53%
18.96
+59.57%
11.88
Pensionand Other Post Retirement Benefit Plans Current
17.72
+21.63%
14.57
+63.37%
8.92
-58.53%
21.51
Current Debt And Capital Lease Obligation
1.70
-60.54%
4.31
-6.01%
4.59
+11.33%
4.12
Current Capital Lease Obligation
1.70
-60.54%
4.31
-6.01%
4.59
+11.33%
4.12
Current Deferred Liabilities
0.90
-88.10%
7.56
0.00
-100.00%
51.78
Current Deferred Revenue
0.90
-88.10%
7.56
0.00
-100.00%
51.78
Total Non Current Liabilities Net Minority Interest
31.55
-4.58%
33.06
-4.73%
34.70
-77.73%
155.84
Long Term Debt And Capital Lease Obligation
25.09
-4.42%
26.25
-21.67%
33.52
-14.03%
38.99
Long Term Capital Lease Obligation
25.09
-4.42%
26.25
-21.67%
33.52
-14.03%
38.99
Non Current Deferred Liabilities
5.87
+0.00%
5.87
0.00
-100.00%
115.65
Non Current Deferred Revenue
5.87
+0.00%
5.87
0.00
-100.00%
109.38
Non Current Deferred Taxes Liabilities
—
—
0.00
-100.00%
6.27
Other Non Current Liabilities
0.58
-37.83%
0.93
-21.40%
1.19
-1.66%
1.21
Stockholders Equity
-14.27
-162.66%
22.77
-72.53%
82.89
-71.90%
294.96
Common Stock Equity
-14.27
-162.66%
22.77
-72.53%
82.89
-71.90%
294.96
Capital Stock
3.51
+64.80%
2.13
+19.48%
1.78
+6.77%
1.67
Common Stock
3.51
+64.80%
2.13
+19.48%
1.78
+6.77%
1.67
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
350.69
+64.77%
212.84
+19.48%
178.13
+6.80%
166.79
Ordinary Shares Number
350.69
+64.77%
212.84
+19.48%
178.13
+6.80%
166.79
Additional Paid In Capital
1,610.94
+5.12%
1,532.49
+2.71%
1,492.08
+2.88%
1,450.24
Retained Earnings
-1,627.25
-8.17%
-1,504.32
-6.96%
-1,406.38
-22.45%
-1,148.55
Gains Losses Not Affecting Retained Earnings
-1.46
+80.56%
-7.53
-63.87%
-4.59
+45.32%
-8.40
Minority Interest
—
—
0.00
0.00
Other Equity Adjustments
-1.46
+80.56%
-7.53
-63.87%
-4.59
+45.32%
-8.40
Total Equity Gross Minority Interest
-14.27
-162.66%
22.77
-72.53%
82.89
-71.90%
294.96
Total Capitalization
-14.27
-162.66%
22.77
-72.53%
82.89
-71.90%
294.96
Working Capital
-6.64
-212.74%
5.89
-87.37%
46.60
-75.30%
188.62
Invested Capital
-14.27
-162.66%
22.77
-72.53%
82.89
-71.90%
294.96
Total Debt
26.80
-12.34%
30.57
-19.78%
38.10
-11.61%
43.11
Capital Lease Obligations
26.80
-12.34%
30.57
-19.78%
38.10
-11.61%
43.11
Net Tangible Assets
-14.27
-162.66%
22.77
-72.53%
82.89
-59.90%
206.68
Tangible Book Value
-14.27
-162.66%
22.77
-72.53%
82.89
-59.90%
206.68
Available For Sale Securities
—
—
—
—
Investmentin Financial Assets
—
—
0.00
-100.00%
29.84
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-97.21
-44.79%
-67.14
+70.14%
-224.84
-0.54%
-223.63
Cash Flow From Continuing Operating Activities
-97.21
-44.79%
-67.14
+70.14%
-224.84
-0.54%
-223.63
Net Income From Continuing Operations
-122.93
-25.52%
-97.94
+62.01%
-257.83
-34.09%
-192.28
Depreciation Amortization Depletion
7.60
-18.79%
9.36
-57.82%
22.19
+7.93%
20.56
Depreciation
7.60
-18.79%
9.36
-57.82%
22.19
+7.93%
20.56
Depreciation And Amortization
7.60
-18.79%
9.36
-57.82%
22.19
+7.93%
20.56
Other Non Cash Items
0.03
-43.86%
0.06
-94.91%
1.12
—
Stock Based Compensation
9.08
-26.68%
12.38
-54.75%
27.36
-13.55%
31.65
Asset Impairment Charge
13.23
+139.72%
5.52
-96.44%
155.01
0.00
Deferred Tax
—
0.00
+100.00%
-6.33
0.00
Deferred Income Tax
—
0.00
+100.00%
-6.33
0.00
Operating Gains Losses
—
-1.03
—
—
Gain Loss On Investment Securities
—
-1.03
—
—
Gain Loss On Sale Of PPE
—
—
—
0.00
Change In Working Capital
-4.22
-193.72%
4.51
+102.75%
-164.03
-99.27%
-82.32
Change In Receivables
0.15
-83.74%
0.95
+197.64%
-0.98
-151.64%
1.89
Changes In Account Receivables
0.15
-60.96%
0.40
-85.59%
2.75
+17.99%
2.33
Change In Prepaid Assets
0.83
-81.07%
4.38
-57.25%
10.26
+308.92%
-4.91
Change In Payables And Accrued Expense
5.85
+169.39%
-8.43
-18.66%
-7.10
-153.20%
13.35
Change In Accrued Expense
3.05
-46.84%
5.74
+145.26%
-12.69
—
Change In Payable
2.79
+119.72%
-14.17
-353.52%
5.59
—
Change In Account Payable
2.79
+119.72%
-14.17
-353.52%
5.59
—
Change In Other Working Capital
-6.66
-149.57%
13.43
+108.33%
-161.16
-78.29%
-90.39
Change In Other Current Liabilities
-4.40
+24.60%
-5.83
-15.36%
-5.06
-123.96%
-2.26
Investing Cash Flow
-0.10
-100.27%
37.52
-75.56%
153.53
+158.97%
59.28
Cash Flow From Continuing Investing Activities
-0.10
-100.27%
37.52
-75.56%
153.53
+158.97%
59.28
Net PPE Purchase And Sale
-0.10
+61.80%
-0.27
+98.74%
-21.16
-4.88%
-20.17
Purchase Of PPE
-0.10
+61.80%
-0.27
+98.74%
-21.16
-4.88%
-20.17
Capital Expenditure
-0.10
+61.80%
-0.27
+98.74%
-21.16
-4.88%
-20.17
Net Investment Purchase And Sale
0.00
-100.00%
35.84
-79.48%
174.69
+119.85%
79.46
Purchase Of Investment
—
0.00
+100.00%
-59.55
+78.53%
-277.39
Sale Of Investment
0.00
-100.00%
35.84
-84.70%
234.24
-34.36%
356.85
Net Business Purchase And Sale
—
—
0.00
0.00
Purchase Of Business
—
—
0.00
0.00
Net Other Investing Changes
—
1.95
—
—
Financing Cash Flow
70.75
+149.32%
28.38
+94.52%
14.59
-82.77%
84.66
Cash Flow From Continuing Financing Activities
70.75
+149.32%
28.38
+94.52%
14.59
-82.77%
84.66
Net Common Stock Issuance
73.67
+154.11%
28.99
+91.92%
15.11
-82.20%
84.87
Proceeds From Stock Option Exercised
0.34
+18.62%
0.29
-68.98%
0.94
-50.66%
1.90
Net Other Financing Charges
-3.26
-260.95%
-0.90
+37.78%
-1.45
+30.94%
-2.10
Changes In Cash
-26.56
-2045.48%
-1.24
+97.82%
-56.72
+28.81%
-79.68
Effect Of Exchange Rate Changes
4.09
+299.76%
-2.05
-238.10%
1.48
+18.26%
1.25
Beginning Cash Position
43.42
-7.04%
46.70
-54.19%
101.94
-43.48%
180.37
End Cash Position
20.95
-51.75%
43.42
-7.04%
46.70
-54.19%
101.94
Free Cash Flow
-97.31
-44.36%
-67.41
+72.60%
-246.00
-0.90%
-243.80
Amortization Of Securities
—
-0.27
+88.28%
-2.33
-87.52%
-1.24
Common Stock Issuance
73.67
+154.11%
28.99
+91.92%
15.11
-82.20%
84.87
Issuance Of Capital Stock
73.67
+154.11%
28.99
+91.92%
15.11
-82.20%
84.87
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category